Adverum Biotechnologies, Inc.

For profitWebsite ↗

Also known as: Adverum Biotechnologies, Inc. | Avalanche Biotechnologies, Inc. | AVALANCHE PHARM

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Dec 1, 2011

Last known activity

Feb 28, 2025

Acquired by Eli Lilly on Oct 24, 2025

Timeline

2000s

Jan 1, 2006
Adverum Biotechnologies, Inc.— Founded

2020s

Oct 24, 2025
Eli Lilly— Acquired By

Drugs by trial phase (5 distinct, 6 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (3 own, 0 via acquisition)

Indications

Studied for

Recent trials (9)

NCT06856577Lead sponsorPhase 3Feb 28, 2025
NCT06856577OfficialPhase 3Feb 28, 2025
NCT05536973Study directorPhase 2Aug 23, 2022
NCT05536973Lead sponsorPhase 2Aug 23, 2022
NCT04418427Lead sponsorPhase 2May 28, 2020
NCT03748784Study directorPhase 1Nov 14, 2018
NCT03748784Lead sponsorPhase 1Nov 14, 2018
NCT02168686Lead sponsorPhase 1/Phase 2Oct 1, 2017
NCT01494805CollaboratorPhase 1/Phase 2Dec 1, 2011

Details

Founded: Menlo Park, CA, US Jan 1, 2006
Last known activity: Feb 28, 2025

Notes

--- Pre-folding founded info: 2016-06-01 Menlo Park CA US https://www.globenewswire.com/news-release/2016/05/12/839388/0/en/Avalanche-Biotechnologies-Closes-Transaction-With-Annapurna-Therapeutics-and-Changes-Name-to-Adverum-Biotechnologies.html ---